Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615503 | 1.00 | ESR1 (0.58) | ESR1IDO1LOXL2HPGDTHRA | |
| SCHEMBL13873209 | 0.93 | ESR1 (0.52) | ESR1IDO1LOXL2HPGDTHRA | |
| SCHEMBL12012736 | 0.87 | ESR1 (0.47) | ESR1HPGDRIPK1 | |
| SCHEMBL6685103 | 0.86 | ESR1 (0.74) | ESR1THRATHRBTAAR1LMNA | |
| SCHEMBL24244771 | 0.82 | ESR1 (0.42) | ESR1IDO1LOXL2HPGDTHRA | |
| SCHEMBL14357053 | 0.81 | HPGD (0.41) | ESR1IDO1LOXL2HPGDTAAR1 | |
| SCHEMBL349725 | 0.80 | SLC6A2 (0.61) | IDO1LOXL2HPGDTAAR1LMNA | |
| SCHEMBL3934371 | 0.80 | IDO1 (0.42) | ESR1IDO1LOXL2HPGDTAAR1 | |
| SCHEMBL4661340 | 0.80 | IDO1 (0.42) | ESR1IDO1LOXL2HPGDTAAR1 | |
| SCHEMBL9025476 | 0.80 | TRPA1 (0.44) | ESR1IDO1LOXL2HPGDTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12048240-B2 | Organic compound, electronic component and electronic apparatus comprising the same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12016896-B2 | Dipeptidomimetics as inhibitors of human immunoproteasomes | CORNELL UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016896-B2 | Dipeptidomimetics as inhibitors of human immunoproteasomes | CORNELL UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024115465-A1 | PHARMACEUTICAL COMPOUNDS AS PARP7 AND/OR PARP1 INHIBITORS | Duke Street Bio Limited (GB) | 2024-06-06 | — | — | WO | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-7192955-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-01-25 | — | — | US | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | ESR1 163/4885IDO1 1082/4885LOXL2 827/4885 |
| US-12048240-B2 | Organic compound, electronic component and electronic apparatus comprising the same | PIEZO1, OCIAD1, OSTC | ESR1 45/4885IDO1 3351/4885LOXL2 606/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | ESR1 4551/4885IDO1 2639/4885LOXL2 495/4885 |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | ESR1 2462/4885IDO1 366/4885LOXL2 712/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | ESR1 4439/4885IDO1 4695/4885LOXL2 2918/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ESR1 4773/4885IDO1 1295/4885LOXL2 4780/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | ESR1 4263/4885IDO1 2643/4885LOXL2 4704/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | ESR1 534/4885IDO1 3963/4885LOXL2 3309/4885 |
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | AOX1, AOC2, OSTC | ESR1 26/4885IDO1 4374/4885LOXL2 537/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | ESR1 2085/4885IDO1 2065/4885LOXL2 1052/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | ESR1 4405/4885IDO1 1734/4885LOXL2 4541/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | ESR1 759/4885IDO1 208/4885LOXL2 2729/4885 |
| US-12016896-B2 | Dipeptidomimetics as inhibitors of human immunoproteasomes | PREP, CTSC, DNPEP | ESR1 2196/4885IDO1 44/4885LOXL2 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.